English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18034/20233 (89%)
造訪人次 : 23779167      線上人數 : 721
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34677


    標題: Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients
    作者: Chen, Tzu-Ju
    Hsu, Bei-Hao
    Lee, Sung-Wei
    Yang, Ching-Chieh
    Tian, Yu-Feng
    Kuo, Yu-Hsuan
    Li, Wan-Shan
    Tsai, Hsin-Hwa
    Wu, Li-Ching
    Yeh, Cheng-Fa
    Chou, Chia-Lin
    Lai, Hong-Yue
    貢獻者: Chi Mei Hospital
    Chung Hua University
    Chung Shan Medical University
    Chung Shan Medical University Hospital
    Chi Mei Hospital
    Chi Mei Hospital
    Chia Nan University of Pharmacy & Science
    Chi Mei Hospital
    Chi Mei Hospital
    Chia Nan University of Pharmacy & Science
    Chi Mei Hospital
    National Sun Yat Sen University
    Chi Mei Hospital
    Chi Mei Hospital
    China Medical University Taiwan
    China Medical University Hospital - Taiwan
    Chi Mei Hospital
    Chia Nan University of Pharmacy & Science
    China Medical University Taiwan
    關鍵字: keratan sulfate
    expression
    glycosaminoglycan
    differentiation
    muc2
    日期: 2022
    上傳時間: 2023-12-11 14:04:41 (UTC+8)
    出版者: FRONTIERS MEDIA SA
    摘要: Objective: To reduce the risk of locoregional recurrence, the addition of neoadjuvant concurrent chemoradiotherapy (CCRT) is recommended before surgical management for rectal cancer patients. However, despite identical tumor histology, individual patient response to neoadjuvant CCRT varies greatly. Accordingly, a comprehensive molecular characterization that is used to predict CCRT efficacy is instantly needed.Methods: Pearson's chi-squared test was utilized to correlate dehydrogenase/reductase 9 (DHRS9) expression with clinicopathological features. Survival curves were created applying the Kaplan-Meier method, and the log-rank test was conducted to compare prognostic utility between high and low DHRS9 expression groups. Multivariate Cox proportional hazards regression analysis was applied to identify independent prognostic biomarkers based on variables with prognostic utility at the univariate level.Results: Utilizing a public transcriptome dataset, we identified that the DHRS9 gene is the most considerably upregulated gene related to epithelial cell differentiation (GO: 0030855) among rectal cancer patients with CCRT resistance. Employing immunohistochemical staining, we also demonstrated that high DHRS9 immunoexpression is considerably associated with an aggressive clinical course and CCRT resistance in our rectal cancer cohort. Among all variables with prognostic utility at the univariate level, only high DHRS9 immunoexpression was independently unfavorably prognostic of all three endpoints (all p <= 0.048) in the multivariate analysis. In addition, applying bioinformatic analysis, we also linked DHRS9 with unrevealed functions, such as keratan sulfate and mucin synthesis which may be implicated in CCRT resistance.Conclusion: Altogether, DHRS9 expression may serve as a helpful predictive and prognostic biomarker and assist decision-making for rectal cancer patients who underwent neoadjuvant CCRT.
    關聯: PATHOLOGY & ONCOLOGY RESEARCH, v.28, n.CB2, pp.CC2, pp.-,
    顯示於類別:[行政單位] 123

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML96檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋